Announced details
Rheumatoid arthritis; polyarticular juvenile idiopathic arthritis; systemic juvenile idiopathic arthritis; Castleman disease; cytokine release syndrome associated with treatment of malignant tumors; and pneumonia caused by SARS-CoV-2
Mochida Pharmaceutical Co.,Ltd. and あゆみ製薬株式会社 have entered into a domestic marketing partnership agreement. Mochida Pharmaceutical Co.,Ltd. will supply the products, and あゆみ製薬株式会社 will market them. Mochida Pharmaceutical Co.,Ltd. and Gedeon Richter Plc. jointly developed these products.
あゆみ製薬株式会社: Head office: Chuo-ku, Tokyo; Representative Director and President: Tsumura Jugo (津村重吾). Gedeon Richter Plc.: No details provided.
Development code: RGB-19. Approval date: 23 March 2026. Registration number and validity period: Not disclosed.
Mochida Pharmaceutical Co.,Ltd.: Shinjuku-ku, Tokyo. あゆみ製薬株式会社: Chuo-ku, Tokyo.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Tocilizumab BS intravenous infusion 80 mg “MA”, Tocilizumab BS intravenous infusion 200 mg “MA”, Tocilizumab BS intravenous infusion 400 mg “MA”, Tocilizumab BS subcutaneous injection 162 mg syringe “MA”, Tocilizumab BS subcutaneous injection 162 mg auto-injector “MA” |
| Counterparty | あゆみ製薬株式会社, Gedeon Richter Plc. |
| Counterparty overview | あゆみ製薬株式会社: Head office: Chuo-ku, Tokyo; Representative Director and President: Tsumura Jugo (津村重吾). Gedeon Richter Plc.: No details provided. |
| Relationship with the Company | Mochida Pharmaceutical Co.,Ltd. and あゆみ製薬株式会社 have entered into a domestic marketing partnership agreement. Mochida Pharmaceutical Co.,Ltd. will supply the products, and あゆみ製薬株式会社 will market them. Mochida Pharmaceutical Co.,Ltd. and Gedeon Richter Plc. jointly developed these products. |
| Applicable area | Rheumatoid arthritis; polyarticular juvenile idiopathic arthritis; systemic juvenile idiopathic arthritis; Castleman disease; cytokine release syndrome associated with treatment of malignant tumors; and pneumonia caused by SARS-CoV-2 |
| Registration number and expiry date | Development code: RGB-19. Approval date: 23 March 2026. Registration number and validity period: Not disclosed. |
| Location | Mochida Pharmaceutical Co.,Ltd.: Shinjuku-ku, Tokyo. あゆみ製薬株式会社: Chuo-ku, Tokyo. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand treatment options for rheumatoid arthritis and other conditions through the launch of these products and meet the needs of patients and healthcare professionals.